Fiocruz

Fuatilia

Most Brazilian states report severe acute respiratory syndrome (SRAG) at alert, risk, or high-risk levels, according to Fiocruz's InfoGripe bulletin released on April 29. Cases are driven mainly by influenza A and respiratory syncytial virus (RSV), which circulate more in autumn and winter. Exceptions are Rio de Janeiro, São Paulo, and Rio Grande do Sul.

Imeripotiwa na AI

Brazil's Fiocruz, through its Farmanguinhos unit, has begun fully domestic production of tacrolimus, an immunosuppressant to prevent organ transplant rejection. The milestone stems from a Product Development Partnership (PDP) with Brazilian firm Libbs, which acquired manufacturing technology from India's Biocon. Farmanguinhos now becomes the sole supplier to the SUS public health system.

Jumatano, 21. Mwezi wa kwanza 2026, 18:14:47

Gilead and Fiocruz sign agreement for HIV injection production in Brazil

Alhamisi, 6. Mwezi wa kumi na moja 2025, 21:34:47

Severe flu cases rise in southeast Brazil, Fiocruz reports

Tovuti hii inatumia vidakuzi

Tunatumia vidakuzi kwa uchambuzi ili kuboresha tovuti yetu. Soma sera ya faragha yetu kwa maelezo zaidi.
Kataa